

Index

A

- ACTs. *See* Artemisinin-based combination therapies (ACTs)
- Acute renal failure (ARF), 10, 13–14
- Ahmed, A.M., 63
- Alderton, G., 85
- 4-Aminoquinolines, 28–29
- 8-Aminoquinolines, 28, 30–31
- AMPs. *See* Antimicrobial peptide (AMPs)
- Anopheles mosquito
 - lysozymes (*see* Lysozymes)
 - parasites transmission, 3, 4
 - sterile insect technique, 38
- Anopheles* sp.
 - An. gambiae*, 60, 98
 - CI and immune system, 61
 - gametocytes, 7
 - I-type lysozymes, 61
 - mosquitoes, 2
 - Musca domestica* and *Drosophila melanogaster*, 60
- Antifolates, 31
- Antimalarial drugs
 - 4-aminoquinolines, 28–29
 - 8-aminoquinolines, 28, 30–31
 - AMPs, 93
 - antibacterial, 97
 - antifolates, 31
 - artemisinin and derivatives, 31–33
 - aryl amino alcohol, 29–30
 - chemotherapy, 13
 - NF- κ B inhibitors, 73
- Antimalarials
 - AMPs, 95
 - Drosophila* and *Anopheles*, 94
 - insect immune response, 94
 - sources, 94
- Antimicrobial peptide (AMPs)
 - antimalarial, 94–95
 - antiplasmodial activity, 93
 - and biologic membranes, 92
 - cecropins, 96–97
 - classification, 91–92
 - defensins, 95
 - dermaseptins, 98
 - DNA synthesis, 92
 - gambicin, 98
 - hydrophobic peptides, 99
 - magainins, 97–98
 - melittin, 97
 - microorganisms, 92
 - mosquitoes, 99
 - Plasmodium*, 93
 - scorpine, 96
 - structure, 93
- ARF. *See* Acute renal failure (ARF)
- Arrighi, R.B., 93
- Arrighi, R.B.G., 62
- Artemisinin
 - ACT, 32
 - chemical structures, 31–32
 - clindamycin, 27
 - factors, 33
 - halofantrine and lumefantrine, 30
 - pregnancy, 32
 - quercetin, 73
- Artemisinin-based combination therapies (ACTs)
 - antimalarial drug, 32
 - and CQ, 27

Artemisinin-based combination therapies

(ACTs) (*cont.*)*P. falciparum* malaria, 27

primaquine, 30

Aryl amino alcohol, 29–30

B

Bannister, L., 6

Basal lamina (BL), 62

Basilico, N., 1–14, 19–38, 59–63

Biomarkers

in clinical practice, 84–85

lysozyme (*see* Lysozyme)

in malaria management, 84

in parasitic infectious diseases, 83–84

plasma, 87–88

BL. *See* Basal lamina (BL)

Blake, C.C., 47

Blood

Anopheles, 7

antimalarial chemotherapy, 26

hemolymph, 63

infection cycle, 6

male mosquito, 4

microscopic diagnosis, 20

P. falciparum, 3*Pf*HRP2, 24*Plasmodium*, 93

“ring stage”, 5

sporozoites, 4

Bloomfield, A.L., 47

Boman, H.G., 93, 96

Brabin, B.J., 11

C

Carballar-Lejarazú, R., 93

Carter, V., 93, 95

Castillo, J.C., 63

Cecropin, 96–97

Cerebral malaria (CM), 10–11, 13, 61

Chloroquine (CQ)

4-amino 7-chloro

quinoline, 28

mefloquine, 30

piperazine, 29

primaquine, 27

CM. *See* Cerebral malaria (CM)

Conde, R., 93

CQ. *See* Chloroquine (CQ)

C-type lysozymes, 49–51

D

Dagan, A., 93

D'Alessandro, S., 1–14, 19–38, 91–99

Defensin, 95

Degranulation

hemozoin (*see* Hemozoin (Hz))

and lysozyme, 67

Dermaseptin, 98

Development

cecropin B, 97

CM, 10

gametocytes, 7

natural immunity, 2

oocysts, 62, 63

P. falciparum, 27

photometric assays, 85

Plasmodium parasite, 60, 95

RDTs, 22

schizont, 4

Diagnosis, malaria. *See* Malaria

Diagnostic (bio)marker, 87

Disease severity. *See* Lysozyme

Dong, Y., 98

Dörmer, P., 12

E

Enzyme-linked immunoadsorbent assay

(ELISA), 24, 85, 87

Epstein, J.E., 34

F

Facchinelli, L., 59–63

Fevold, H.L., 85

Fleming, A., 45–47

G

Gambicin, 94, 96, 98

Ghosh, J.K., 93

Giribaldi, G., 1–14, 67–78, 91–99

Glucose-6-phosphate dehydrogenase (G6PD),

26–27, 30

Golgi, C., 2

G6PD. *See* Glucose-6-phosphate

dehydrogenase (G6PD)

Gram-negative bacteria, 50–52

Gram-positive bacteria, 50–52

Grassi, G.B., 3

G-type lysozymes, 49–51

Gwadz, R.W., 93

H

- Hartsell, S.E., 85
 Helix-loop-helix peptide, 51
 Hemozoin (Hz)
 degranulation, 69
 HDP, 24
 intraerythrocytic stages, 8
 lysosomal phosphatases and glycosidases, 8
 malarial pigment, 8–9
 MMP-9, 9–10
 phagocytosis, 9, 68, 88
 x-ray diffraction, 8
 Herrera-Ortiz, A., 95
 HETE. *See* 15-Hydroxyeicosatetraenoic (HETE)
 HODEs. *See* Hydroxy-octadecadienoic (HODEs)
 Human lysozymes
 biomarkers (*see* Biomarkers)
 plasma levels, 87–88
 Human malaria, 10, 13, 71, 72
 Hydroxy-octadecadienoic (HODEs), 74, 75, 77
 15-Hydroxyeicosatetraenoic (HETE)
 and 4-HNE, 75
 HODEs, 74
 lysozyme release, 75
 MIP-1 α /CCL3, 76
 NF- κ B pathway, 77–78
 and p38 MAPK, 77

I

- Ibrahim, H.R., 52
 Immune system
 AMPs, 91
 bacterial infections, 47
 defensins, 95
 oocysts, 62
 Immunohistochemistry (IHC), 86–87
 Inflammation
 erythropoiesis, SMA, 12
 high mobility group box 1 (HMGB1), 25
 and infection, pregnancy, 25
 I-type lysozymes, 50, 51

K

- Kajla, M.K., 61–63
 Kang, D., 60
 Krugliak, M., 93

L

- Laschtschenko, P., 47
 Lipocalin, 88
 Litwack, G., 85
 Lucchi, N.W., 73
LysC1
 mosquito hemolymph, 63
 P. berghei infections, 62
 peptidoglycan fragments, 61
LysC2, 60
 Lysozyme antimicrobial
 properties, 47
 Lysozyme functions, 47, 50
 Lysozymes
 alpha helix, 49
 Anopheles gambiae, 60
 antibacterial defense, 50, 59
 antimicrobial action, 47
 antimicrobial function,
 51–52
 applications, 48
 beta-glycosidic linkage, 49
 biological fluids, 47
 Candida albicans, 52
 c- and i-type lysozymes, 60
 cathepsins G and D, 52
 cell wall modifications, 51
 C-type lysozymes, 50
 cytokine levels, 71
 description, 45
 ELISA, 87
 Gram-negative bacteria, 50–51
 Gram-positive microorganisms,
 48, 50
 G-type lysozyme, 50
 helix-loop-helix peptide, 51
 IHC, 86–87
 IL-1 β production, 70–71
 I-type lysozymes, 50
 mechanism, 71–72
 Micrococcus lysodeikticus, 47
 and penicillin, 47
 peptidoglycan recognition
 proteins, 60
 photometric assays, 85–86
 Plasmodium, 61–63
 RIA, 86
 Staphylococcus aureus culture and
 Penicillium spp., 46
 TNF- α , 69–70
 urine and serum, 48

M

Magainin, 97–98

Malaria

- anopheles species, 3
- ARF, 13–14
- blood cells, 2
- CM, 10–11
- cyclical fever, 2
- description, 1–2, 10
- hemozoin (*see* Hemozoin (Hz))
- HETE, 74–78
- human infections, 2
- human monocytes, 67–68
- and LysC1, 62
- lysozyme (*see* Lysozyme)
- MAPK, 72–74
- natural immunity, children, 2
- Plasmodium falciparum* life cycle, 3–8
- Plasmodium* parasites, 67
- RBCs, 2–3
- RD, 12–13
- SMA, 11–12
- symptoms, 2

Malaria diagnosis

- clinical signs and symptoms, 20
- dihydrofolate reductase (DHFR), 25
- erythrocytes, 25
- glutamate-rich protein (GLURP), 25
- heat-shock proteins (HSPs), 24
- heme detoxification protein (HDP), 24–25
- high mobility group box 1 (HMGB1), 25
- microscopic diagnosis, 20–22
- molecular diagnosis, 25–26
- P. falciparum*, 19
- RDTs (*see* Rapid diagnostic tests (RDTs))

Malaria treatment

- antimalarial drugs (*see* Antimalarial drugs)
- G6PD, 26–27
- P. vivax* and *P. ovale*, 26
- severe malaria, 27
- uncomplicated malaria, 27

Malaria vaccines

- artemisinin and insecticide resistance, 33
- blood stage, 35
- characteristics, 33
- life cycle stages, 34
- PfEMP1*, 33
- preerythrocytic, 34
- transmission-blocking, 35–36

MAPK. *See* Mitogen-activated protein kinase (MAPK)

Matrix metalloproteinase-9 (MMP-9), 9–10

Melittin, 97

Micrococcus lysodeikticus, 47, 85

Microscopic diagnosis

- leukocytes, 22
- P. knowlesi*, 22
- Plasmodium*, 20, 21
- thick and blood smear, 20, 22
- WBCs and RBCs, 20

Mild malaria, 83, 88

Mitchell, G., 6

Mitogen-activated protein kinase (MAPK)

- c*-lysozyme gene, 73
- and NF- κ B, 72
- PfGPI*, 72–73
- signaling pathways, 74

MMP-9. *See* Matrix metalloproteinase-9 (MMP-9)

Mohammed, A.O., 88

Molecular diagnosis, 25–26

Monocyte. *See* Malaria

Mosquito

- anopheles mosquito
- (*see* Anopheles mosquito)
- malaria (*see* Malaria)
- transgenic mosquitoes, 37–38

Mosquito immunity

- cecropins, 96–97
- defensins, 95–96
- dermaseptins, 98
- gambicin, 98
- magainins, 97–98
- scorpion venom, 96

Myeloperoxidase, 88

N

Nacer, A., 62

N-acetylglucosamine, 85*N*-acetylmuramic acid, 49, 50, 59, 85Neutrophil. *See* MalariaNuclear factor-kappaB (NF- κ B)

- HETEs, 77–78
- and p38 MAPK, 72–74

O

Oakley, M.S., 2

Oliva, C., 59–63

Oocyst

- Aedes aegypti*, 95
- basal lamina (BL), 62
- cecropin B, 97
- P. berghei* infections, 62
- sporozoites, 7

P

- Peptidoglycan catalysis, 49
 Perkins, D.J., 12
PfEMP. *See Plasmodium falciparum*
 erythrocyte membrane protein (*PfEMP*)
 Phagocytosis
 hemozoin (*see* Hemozoin (Hz))
 human monocytes, 71
 Photometric assay, 85–86
 Plasma
 lysozyme, lipocalin and myeloperoxidase, 88
 neutrophil, 88
P. falciparum, 87
Plasmodium falciparum
 and *An. gambiae*, 61–62
 and *Anopheles* mosquito species, 3, 4
 BL, 62
 circumsporozoite protein, 33
 erythrocytic stage, 5–7
 glycosaminoglycans, 62
 liver stage, 4–5
 LysC1, 62–63
 mosquito, 7–8
P. berghei infections, 62
 phenoloxylase activity (PO), 63
P. parasite, 2
 sporozoites, 4, 34
 trophozoites, 22
Plasmodium falciparum erythrocyte
 membrane protein (*PfEMP*), 5, 33, 35
Plasmodium falciparum
 glycosylphosphatidylinositol (*PfGPI*),
 72–73
 Polimeni, M., 45–52, 67–78, 83–88
 Possani, L.D., 99
 Prato, M., 1–14, 67–78, 83–88
 Prognosis, 83
 Prognostic (bio)marker, 84
 Pro-inflammatory cytokines, 68–69
 Prospective study, 85, 87

Q

Quinine, 30

R

- Radioimmunoassay (RIA), 86
 Rao, X.-J., 63
 Rapid diagnostic tests (RDTs), 20, 22–24, 26
 RBCs. *See* Red blood cells (RBCs)
 RD. *See* Respiratory distress (RD)

RDTs. *See* Rapid diagnostic tests (RDTs)

- Red blood cells (RBCs)
 and AMPs, 93
 CM, 10
 dermaseptins, 98
 dyserythropoiesis and bone
 marrow, 12
 merozoites, 5
 peripheral blood parasitemia, 24
PfEMP, 5
P. vivax, 2
 schizonts, 6
 thick blood films, 20
 Respiratory distress (RD), 12–13
 RIA. *See* Radioimmunoassay (RIA)
 Ridley, F.T., 45, 46
 “Ring stage”, 5, 6
 Rivas, L., 99
 RTS,S, 33, 34

S

- Schizont
 merozoites, 4
P. falciparum and *P. malariae*, 4
 quinine, 29
 RBCs, 2, 68
 trophozoites, 6
 Scorpine, 96
 Severe malaria
 diagnosis, 69
 neutrophil activation, 88
 quinine, 30
 and uncomplicated, 88
 Severe malarial anemia (SMA), 11–12
 Shahabuddin, M., 93
 Smolelis, A.N., 85
 Spaccapelo, R., 19–38, 45–52,
 59–63

T

- Tissue
 antibacterial defense, 50
 lysozyme gene, 49
 and MMP-9, 67
 mosquitoes, 95
 Trophozoite
 erythrocytes, 5
 hemoglobin, 8
 schizonts, 6
 Tullio, V., 45–52, 83–88, 91–99

U

Urine

- macrophages, 76
- and serum, 85

V

Vector control, malaria

- ITNs and IRS, 36
- organochlorines (OCs) and carbamates (Cs), 36–37

pyrethroids, 36, 37

transgenic mosquitoes,
37–38

Vizioli, J., 93

W

Wade, D., 93, 97

White blood cells
(WBCs), 20

Wilson, M.L., 23